Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Practical, safe, and effective hemostatic approach to orthopedic surgery using Extended Half-Life factor IX in hemophilia B. By intraindividual comparison, we found a lower FIX consumption, number of infusions, and cost compared to plasma-derived FIX.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069879 | PMC |
| http://dx.doi.org/10.1002/ccr3.2450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factor VIII Pharmacokinetics in Mexican Patients With Hemophilia A.
Arch Med Res
September 2025
Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Electronic address:
Introduction: Treatment of patients with severe hemophilia A requires the replacement of deficient factor VIII. To reach the international standards of care, an optimal dose of factor VIII should be administered based on pharmacokinetic analysis. However, in Mexico factor VIII pharmacokinetics is not used.
View Article and Find Full Text PDFA self-healing micellar hydrogel system for controlled release of caffeic acid phenethyl ester and durable inhibition of prostate tumor.
Int J Biol Macromol
September 2025
Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan; PhD Program for Aging and Graduate Institute of Basic Medical Science, China Medical University, Taichung City 40402, Taiwan; Biotechnology Center, National Chung Hsing University, Taichung City 402
Hydrogel-encapsulation allows slow and stable delivery of drugs with short half-lives, avoiding the undesired side effects of high-dose or frequent administration of drugs. We previously reported that gavage or injection of caffeic acid phenethyl ester (CAPE) at 10-15 mg/kg, 2-3 times per week effectively repressed the tumor growth of human prostate xenografts in nude mice. However, daily oral or injectable delivery of CAPE in prostate cancer (PCa) patients may be impractical due to forgetfulness, physical limitations, or treatment fatigue.
View Article and Find Full Text PDFClesrovimab: First Approval.
Drugs
September 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Clesrovimab (ENFLONSIA™; clesrovimab-cfor) is a long-acting monoclonal antibody developed by Merck & Co., Inc. to prevent respiratory syncytial virus (RSV) disease in infants.
View Article and Find Full Text PDFRational design of a bispecific antibody for rapid and prolonged neutrophil mobilization and proliferation.
Int Immunopharmacol
September 2025
Key Laboratory of Biomacromolecules (CAS), CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Beijing Translational Center for Biopharmaceuticals; Chaoyang District, Beijing 100101, China; Suzhou Institute for Biomedical Resea
Human granulocyte colony stimulating factor (G-CSF) and the G-protein C-X-C chemokine receptor 4 (CXCR4)/stromal cell-derived factor-1 (SDF-1) axis play pivotal roles in neutrophil mobilization, differentiation and proliferation. Bispecific antibodies represent a viable therapeutic strategy by simultaneously targeting these two granulocyte-associated receptors while providing an extended half-life. In this study, we engineered a bispecific antibody by grafting human G-CSF and a synthetic anti-CXCR4 peptide into the heavy chain complementarity-determining region 3 (CDR3) of the humanized antibody Herceptin.
View Article and Find Full Text PDFEnhancing employee well-being through a culturally adapted training program: a mixed-methods study in South Africa.
Front Public Health
September 2025
Department of Industrial Psychology and People Management, College of Business and Economics, University of Johannesburg, Johannesburg, South Africa.
Introduction: Structured, well-being interventions are under-researched in non-Western workplaces. This study evaluates training program-a participatory, multi-component training intervention-on employee well-being, engagement and stress in South Africa.
Methods: Employing an exploratory, quasi-experimental, explanatory sequential mixed-methods design, we collected quantitative data from 50 South African respondents across three delivery formats (four half-days online, two full-days in classroom, and four half-days in classroom) at pre-training and 3 months post-training using five validated scales (PSS-4, UWES-3, SWLS, FS, WEMWBS-14).